Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | CD44 | P16070 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 5/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HTR5A | P47898 | 1/20 | 0.32 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.32 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL222039 | 0.87 | PARP1 (0.37) | MAPTCYP3A4PNMTCD44MAOB | |
| SCHEMBL223760 | 0.85 | TDP1 (0.30) | MAPTCYP3A4KDM4EBCHEACHE | |
| SCHEMBL4440098 | 0.77 | POLB (0.35) | CYP3A4PDCD1CD274HTR2CHTR2A | |
| SCHEMBL4909847 | 0.76 | BCHE (0.45) | CYP3A4KDM4EBCHEACHECACNB4 | |
| SCHEMBL1532144 | 0.76 | BCHE (0.45) | CYP3A4KDM4EBCHEACHECACNB4 | |
| SCHEMBL4464318 | 0.75 | BCHE (0.46) | CYP3A4KDM4EBCHEACHECACNB4 | |
| SCHEMBL6312249 | 0.73 | HTR2C (0.47) | MAPTCYP3A4PNMTCD44MAOB | |
| SCHEMBL6313436 | 0.70 | HTR2C (0.48) | MAPTCYP3A4PARP1TNKS2PARP2 | |
| SCHEMBL30751773 | 0.67 | CYP3A4 (0.55) | MAPTCYP3A4PNMTCD44MAOB | |
| SCHEMBL2401358 | 0.67 | CYP3A4 (0.55) | MAPTCYP3A4PNMTCD44MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156742-A1 | TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2024-05-16 | — | — | US | disclosed |
| US-20240148886-A1 | INTRACELLULAR DELIVERY COMPOSITIONS | BIOND BIOLOGICS LTD. (IL) | 2024-05-09 | — | — | US | disclosed |
| US-20240025886-A1 | INHIBITORS OF IGF2BP1-RNA BINDING | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-01-25 | — | — | US | disclosed |
| US-20230201201-A1 | COMPOSITION FOR USE IN THE TREATMENT OF APOL1-ASSOCIATED DISEASE | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2023-06-29 | — | — | US | disclosed |
| US-20230124527-A1 | NANOPARTICLES FOR CHEMIRESISTOR SENSORS | NANOSCENT LTD. (IL) | 2023-04-20 | — | — | US | disclosed |
| US-20230104413-A1 | NANOPARTICLES FOR CHEMIRESISTOR SENSORS | NANOSCENT LTD. (IL) | 2023-04-06 | — | — | US | disclosed |
| US-11358931-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| EP-4004127-A1 | COATING COMPOSITIONS WITH POLYSILOXANE-MODIFIED CARBON NANOPARTICLE | Valfre' di Bonzo, Roberto (CH) | 2022-06-01 | — | — | EP | disclosed |
| US-11307158-B1 | Nanoparticles for chemiresistor sensors | NANOSCENT LTD. (IL) | 2022-04-19 | — | — | US | disclosed |
| WO-2021014430-A1 | COATING COMPOSITIONS WITH POLYSILOXANE-MODIFIED CARBON NANOPARTICLE | VALFRE' DI BONZO, Roberto (CH) | 2021-01-28 | — | — | WO | disclosed |
| WO-2009128918-A1 | COMBINATION THERAPY USING A SOLUBLE HYALURONIDASE AND A BISPHOSPHONATE | HALOZYME, INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| US-7582794-B2 | Process for the preparation of substituted 2-(phenoxymethyl)benzoic acids | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| WO-2009082437-A2 | SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009009117-A2 | CHEMOENZYMATIC PROCESSES FOR PREPARATION OF LEVETIRACETAM | BIOVERDANT, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| EP-1699748-B1 | METHOD FOR THE PRODUCTION OF SUBSTITUTED 2-(PHENOXYMETHYL)-BENZOIC ACIDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-10-15 | — | — | EP | disclosed |
| US-20070219395-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-(PHENOXYMETHYL)BENZOIC ACIDS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| US-7238835-B2 | Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-03 | — | — | US | disclosed |
| EP-1699748-A2 | METHOD FOR THE PRODUCTION OF SUBSTITUTED 2-(PHENOXYMETHYL)-BENZOIC ACIDS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-09-13 | — | — | EP | disclosed |
| US-20050171205-A1 | Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-04 | — | — | US | disclosed |
| WO-2005061427-A2 | METHOD FOR THE PRODUCTION OF SUBSTITUTED 2-(PHENOXYMETHYL)-BENZOIC ACIDS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201201-A1 | COMPOSITION FOR USE IN THE TREATMENT OF APOL1-ASSOCIATED DISEASE | APOL1, APOB, LIPA | MAPT 689/4885CYP3A4 4439/4885PNMT 3826/4885 |
| US-20070219395-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED 2-(PHENOXYMETHYL)BENZOIC ACIDS | CYP2B6, CYP1B1, CYP4B1 | MAPT 4159/4885CYP3A4 24/4885PNMT 1543/4885 |
| US-20240156742-A1 | TARGETED MULTIFUNCTIONAL NANOSTRUCTURED LIPID CARRIERS | LCAT, CD47, PHOSPHO1 | MAPT 913/4885CYP3A4 4794/4885PNMT 890/4885 |
| US-20240148886-A1 | INTRACELLULAR DELIVERY COMPOSITIONS | ACTB, CHERP, EEA1 | MAPT 627/4885CYP3A4 4851/4885PNMT 4517/4885 |
| US-20050171205-A1 | Process for the preparation of substituted 2-(phenoxymethyl) benzoic acids | CYP2B6, CYP1B1, CYP4B1 | MAPT 4159/4885CYP3A4 24/4885PNMT 1543/4885 |
| US-11358931-B2 | Selective androgen receptor modulators (SARMs) and uses thereof | AR, NR5A1, SHBG | MAPT 3495/4885CYP3A4 585/4885PNMT 1602/4885 |
| US-20240025886-A1 | INHIBITORS OF IGF2BP1-RNA BINDING | IGF2BP1, IGF2BP2, IGF2BP3 | MAPT 2590/4885CYP3A4 4862/4885PNMT 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.